The Advisory Board of ADC Review | Journal of Antibody-drug Conjugates includes physicians (including oncologists and hematologists), scientists, industry experts/Key Opinion Leaders (KOL), and regulators from a broad range of backgrounds and expertise that include:
- Clinical oncology and hematology practice innovation, management, public policy, professional advocacy and education.
- Actively managing successful clinical practices, teaching at major universities and hospitals, holding senior management positions at medical associations, research institutes / laboratories, pharmaceutical and life-science companies, governmental agencies and major insurance companies.
- Impressive level of healthcare experience, enabling us to offer innovation, education, advocacy and best practices to our readers.
